Genentech USA, Inc.
Genentech USA, Inc., a pioneering biotechnology company, is headquartered in South San Francisco, California. Founded in 1976, Genentech has established itself as a leader in the biopharmaceutical industry, focusing on the development of innovative therapies for serious medical conditions, particularly in oncology, immunology, and neuroscience. With a commitment to research and development, Genentech has introduced groundbreaking products such as Herceptin and Avastin, which have transformed treatment protocols for various cancers. The company is renowned for its robust pipeline and dedication to personalised medicine, setting it apart in a competitive market. Recognised for its contributions to healthcare, Genentech has received numerous accolades, solidifying its position as a key player in the biotechnology sector. Its ongoing commitment to scientific advancement continues to drive its success and influence in the industry.
DitchCarbon Score
How does Genentech USA, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genentech USA, Inc.'s score of 38 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Genentech USA, Inc.'s reported carbon emissions
Genentech USA, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their current impact on climate change or the effectiveness of their sustainability initiatives. However, the company is likely engaged in industry-standard practices aimed at reducing carbon footprints and addressing climate commitments. As the pharmaceutical sector increasingly focuses on sustainability, Genentech may be exploring various strategies to enhance its environmental performance in line with global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Genentech USA, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
